Last reviewed · How we verify
NCT03854552
A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.
Phase 1 trial testing BI 764198 in Healthy in 72 participants. Completed in 7 August 2019.
7 August 2019
Quick facts
| Lead sponsor | Boehringer Ingelheim |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 15 March 2019 |
| Primary completion | 7 August 2019 |
| Estimated completion | 7 August 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- BI 764198 — full drug profile →
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Boehringer Ingelheim — full company profile →
Who can join
Adults 18 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this trial is to investigate safety and tolerability of BI 764198 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) including dose proportionality of BI 764198 after single oral dosing.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design.
Trachtman H, Kretzler M, Desmond HE, Choi W, et al · · 2023 · cited 21× · PMID 38106603 · DOI 10.1016/j.ekir.2023.09.026 -
Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy.
Lin BL, Shin JY, Jeffreys WP, Wang N, et al · · 2022 · cited 20× · PMID 36099033 · DOI 10.1172/jci.insight.158906 -
Transient Receptor Potential Canonical 6 (TRPC6) Channel in the Pathogenesis of Diseases: A Jack of Many Trades.
Saqib U, Munjuluri S, Sarkar S, Biswas S, et al · · 2023 · cited 18× · PMID 37072606 · DOI 10.1007/s10753-023-01808-3 -
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment.
Schultz A, Halabi A, Seitz F, Lemmens K, et al · · 2025 · cited 3× · PMID 40455255 · DOI 10.1080/13543784.2025.2510673 -
Physiological functions and pharmacological targeting of transient receptor potential channels.
Chubanov V, Grimm C, Hill K, Schaefer M, et al · · 2025 · PMID 41118703 · DOI 10.1016/j.pharmr.2025.100089
Verify or expand the search:
- PubMed search for NCT03854552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BI 764198
Trials testing the same drug.
- NCT07355296 — PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease · Phase 2 · recruiting
- NCT07220083 — A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc · Phase 3 · recruiting
- NCT07308652 — A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 764198 in the Blood · Phase 1 · completed
- NCT07368569 — A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body · Phase 1 · completed
- NCT05213624 — A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis · Phase 2 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Boehringer Ingelheim trials
Trials by the same sponsor.
- NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
- NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
- NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
- NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03854552 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
- Last refreshed: 8 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03854552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing